循环microRNA-95和-190在甲状腺结节鉴别诊断中的诊断价值:1000例连续患者的验证研究
本研究前瞻性分析1000例甲状腺结节患者,验证血清miRNA-190与-95组合(pmiRNA)的诊断效能。结果显示pmiRNA联合细针穿刺细胞学(FNAC)使敏感性升至96.3%,高于单独FNAC的88.9%和单独pmiRNA的89.6%,假阴性由18例(FNAC)和17例(pmiRNA)降至5例。结论认为该组合是意大利人群中甲状腺结节鉴别诊断准确、无创的工具。
要点
- pmiRNA联合FNAC敏感性96.3%,高于单独FNAC的88.9%和单独pmiRNA的89.6%。
- 联合检测将假阴性从FNAC的18例和pmiRNA的17例降至5例。
- 在FNAC未做、取材不足或结果不确定并接受手术者中,pmiRNA正确识别90.8%良性病例和74.3%癌症病例。
核心结论
- 结果证实血清miRNA-95和-190表达水平的组合是意大利人群中甲状腺结节鉴别诊断准确且无创的工具。
研究设计与样本
- 前瞻性分析1000例患者,细胞学诊断可获取982/1000(98.2%),组织学诊断可获取445/1000(44.5%)。
- 采用实时聚合酶链反应以2-ΔΔct法测定循环miRNA-190和-95的表达水平。
- 将FNAC、pmiRNA及两者联合的诊断性能(敏感性、特异性、准确性)与细胞学和组织学诊断进行相关性分析。
主要发现
- pmiRNA联合FNAC的敏感性为96.3%,高于单独FNAC的88.9%和单独pmiRNA的89.6%。
- 联合检测将假阴性从FNAC的18例和pmiRNA的17例降至仅5例。
- 在未行FNAC(n=14)、取材不足(n=18)或结果不确定(n=72)并接受手术的患者中,pmiRNA正确识别90.8%的良性疾病患者和74.3%的癌症患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has recently been demonstrated that the combination of miRNA-190 and -95 (expressed as probability of malignant risk: pmiRNA) in the serum of Caucasian patients with thyroid nodular disease allows the identification of nodules at high risk of malignancy with great accuracy. The present study aimed to validate these results in a larger cohort of patients. MATERIALS AND METHODS: This study prospectively analyzed 1000 patients. Cytological diagnosis was available in 982/1000 (98.2%) and histological diagnosis in 445/1000 (44.5%). The expression levels of circulating miRNA-190 and -95 were determined by real time polymerase chain reaction with the 2-ΔΔct method. The diagnostic performance (sensitivity, specificity, and accuracy) of fine-needle aspiration cytology (FNAC), pmiRNA, and a combination of the two methods was correlated with the cytological and histological diagnoses. RESULTS: The combination of pmiRNA and FNAC significantly increased the sensitivity (96.3%) with respect to each method alone (88.9% for FNAC and 89.6% for pmiRNA) by reducing the rate of false-negative results from 18 for FNAC and 17 for pmiRNA to only five. In patients in whom FNAC was not performed (n = 14) or in those with inadequate (n = 18) or indeterminate (n = 72) lesions submitted to surgery, pmiRNA correctly identified 90.8% of patients with benign disease and 74.3% of patients with cancer. CONCLUSIONS: These results confirm that a combination of serum expression levels of miRNA-95 and -190 is an accurate and noninvasive tool for the differential diagnosis of thyroid nodules in the Italian population.
引用
- Pilli T, Cantara S, Marzocchi C, et al. Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients. Thyroid. 2017. PMID: 28605303. doi:10.1089/thy.2017.0035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。